|
|
Kazuya Takahashi, Sachiko Miyake, Takayuki Kondo, Keiji Terao, Megumi Hatakenaka, Shuji Hashimoto, Takashi Yamamura
J Clin Invest. 2001;
107(5):0
doi:10.1172/JCI11819
Abstract |
Full text
| PDF

M
ultiple sclerosis (MS) is an autoimmune disease characterized by clinical relapse and remission. Because of the potential role of natural killer (NK) cells in the regulation of autoimmunity, we have examined cytokine profile and surface phenotype of NK cells in the peripheral blood of MS. Here we demonstrate that NK cells in the remission of MS are characterized by a remarkable elevation of IL-5 mRNA and a decreased expression of IL-12Rβ2 mRNA, as well as a higher expression of CD95. Moreover, the NK cells from MS in remission produced much larger amounts of IL-5 than did those from controls after stimulation with phorbol myristate acetate (PMA) and ionomycin. These features are reminiscent of those of NK type 2 (NK2) cells that can be induced in a condition favoring functional deviation of T cells toward Th2. Remarkably, the NK cells lose the NK2-like property when relapse of MS occurs, but regain it after recovery. We also found that NK2 cells induced in vitro inhibit induction of Th1 cells, suggesting that the NK2-like cells in vivo may also prohibit autoimmune effector T cells. Taken together, it is possible that NK cells play an active role in maintaining the remission of MS.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(33)
| Title and authors |
Publication |
Year |
Cho-kyung-jong-ok-tang, a traditional Korean herbal formula induces type 2 shift in murine natural killer cell cytokine production
Han-Sung Lee, Kwang-Ho Cho, Tae-Kyung Kim, Choon-Hwan Kim, Soo-Jung Ahn, Eun-Hui Lee, Kyoo-Seok Ahn, Yun-Jae Jung
|
Journal of Ethnopharmacology
|
2011 |
Mucosal-associated invariant T cells regulate Th1 response in multiple sclerosis
Y. Miyazaki, S. Miyake, A. Chiba, O. Lantz, T. Yamamura
|
International Immunology
|
2011 |
Increase of Ki-67+ natural killer cells in multiple sclerosis patients treated with interferon-β and interferon-β combined with low-dose oral steroids
Lara Sanvito, Atsuko Tomita, Norio Chihara, Tomoko Okamoto, Youwei Lin, Masafumi Ogawa, Bruno Gran, Toshimasa Aranami, Takashi Yamamura
|
Journal of Neuroimmunology
|
2011 |
Natural killer cells as indispensable players and therapeutic targets in autoimmunity
Fu-Dong Shi, Qinghua Zhou
|
Autoimmunity
|
2011 |
It is still not for the old iron: adjuvant effects of carbonyl iron in experimental autoimmune encephalomyelitis induction
Djordje Miljković, Miljana Momčilović, Željka Stanojević, Dejan Rašić, Marija Mostarica-Stojković
|
Journal of Neurochemistry
|
2011 |
Tolerogen-induced interferon-producing killer dendritic cells (IKDCs) protect against EAE
Eduardo Huarte, Agnieszka Rynda-Apple, Carol Riccardi, Jerod A. Skyberg, Sarah Golden, MaryClare F. Rollins, Andrew G. Ramstead, Larissa O. Jackiw, Massimo Maddaloni, David W. Pascual
|
Journal of Autoimmunity
|
2011 |
Analysis of the cellular mechanism underlying inhibition of EAE after treatment with anti-NKG2A F(ab')2.
Jianmei W Leavenworth, Carola Schellack, Hye-Jung Kim, Linrong Lu, Pieter Spee, Harvey Cantor
|
Proc. Natl. Acad. Sci. U.S.A.
|
2010 |
Role of the innate immune system in the pathogenesis of multiple sclerosis.
Roopali Gandhi, Alice Laroni, Howard L Weiner
|
Journal of Neuroimmunology
|
2010 |
Multiple sclerosis: risk factors, prodromes, and potential causal pathways
Sreeram V Ramagopalan, Ruth Dobson, Ute C Meier, Gavin Giovannoni
|
The Lancet Neurology
|
2010 |
Anticipated benefits and surprising effects of daclizumab in multiple sclerosis
Olaf Stüve, Benjamin M Greenberg
|
The Lancet Neurology
|
2010 |
|